Tardive Dyskinesia Associated with Atypical Antipsychotics: Prevalence, Mechanisms and Management Strategies

CNS Drugs

Volumn 32, Issue 2, 2018, Pages 135-147

  Stegmayer, Katharina ^a   Walther, Sebastian ^a   van Harten, Peter ^b,c  

^a UNIVERSITY OF BERN   (Switzerland)

^b Psychiatric Centre GGZ Centraal   (Netherlands)

^c MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; BOTULINUM TOXIN; CLOZAPINE; DOPAMINE RECEPTOR; PROTEIN INHIBITOR; NEUROLEPTIC AGENT;

HUMAN; MEDLINE; OXIDATIVE STRESS; PREVALENCE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SYSTEMATIC REVIEW; TARDIVE DYSKINESIA; DISEASE MANAGEMENT; MENTAL DISEASE; STATISTICS AND NUMERICAL DATA;

ANTIPSYCHOTIC AGENTS; DISEASE MANAGEMENT; HUMANS; MENTAL DISORDERS; PUBMED; TARDIVE DYSKINESIA;

EID: 85041845010     PISSN: 11727047     EISSN: 11791934     Source Type: Journal    
DOI: 10.1007/s40263-018-0494-8     Document Type: Review

References (149)

1. Walther S, Strik W. Motor symptoms and schizophrenia. Neuropsychobiology. 2012;66(2):77–92. https://doi.org/10.1159/000339456.
2. Aquino CC, Lang AE. Tardive dyskinesia syndromes: current concepts. Parkinsonism Relat Disord. 2014;20(Suppl 1):S113–7. https://doi.org/10.1016/S1353-8020(13)70028-2.
3. Peralta V, Cuesta MJ. Neuromotor abnormalities in neuroleptic-naive psychotic patients: antecedents, clinical correlates, and prediction of treatment response. Compr Psychiatry. 2011;52(2):139–45. https://doi.org/10.1016/j.comppsych.2010.05.009.
4. Peralta V, Campos MS, De Jalon EG, Cuesta MJ. Motor behavior abnormalities in drug-naive patients with schizophrenia spectrum disorders. Mov Disord. 2010;25(8):1068–76. https://doi.org/10.1002/mds.23050.
5. Peralta V, Cuesta MJ. The effect of antipsychotic medication on neuromotor abnormalities in neuroleptic-naive nonaffective psychotic patients: a naturalistic study with haloperidol, risperidone, or olanzapine. Prim Care Companion J Clin Psychiatry. 2010. https://doi.org/10.4088/pcc.09m00799gry.
6. Kindler J, Schultze-Lutter F, Michel C, Martz-Irngartinger A, Linder C, Schmidt SJ, et al. Abnormal involuntary movements are linked to psychosis-risk in children and adolescents: results of a population-based study. Schizophr Res. 2016. https://doi.org/10.1016/j.schres.2016.04.032.
7. Walther S, Stegmayer K, Horn H, Rampa L, Razavi N, Muller TJ, et al. The longitudinal course of gross motor activity in schizophrenia—within and between episodes. Front Psychiatry. 2015;6:10. https://doi.org/10.3389/fpsyt.2015.00010.
8. Walther S, Stegmayer K, Horn H, Razavi N, Muller TJ, Strik W. Physical activity in schizophrenia is higher in the first episode than in subsequent ones. Front Psychiatry. 2014;5:191. https://doi.org/10.3389/fpsyt.2014.00191.
9. van Harten PN, Walther S, Kent JS, Sponheim SR, Mittal VA. The clinical and prognostic value of motor abnormalities in psychosis, and the importance of instrumental assessment. Neurosci Biobehav Rev. 2017;80:476–87. https://doi.org/10.1016/j.neubiorev.2017.06.007.
10. Peralta V, Cuesta MJ. Motor abnormalities: from neurodevelopmental to neurodegenerative through “functional” (neuro) psychiatric disorders. Schizophr Bull. 2017;43(5):956–71. https://doi.org/10.1093/schbul/sbx089.
11. Cornett EM, Novitch M, Kaye AD, Kata V, Kaye AM. Medication-induced tardive dyskinesia: a review and update. Ochsner J. 2017;17(2):162–74.
12. Ayd FJ Jr. A survey of drug-induced extrapyramidal reactions. JAMA. 1961;175:1054–60.
13. Meltzer HY, Matsubara S, Lee JC. The ratios of serotonin2 and dopamine2 affinities differentiate atypical and typical antipsychotic drugs. Psychopharmacol Bull. 1989;25(3):390–2.
14. Markowitz JS, Brown CS, Moore TR. Atypical antipsychotics. Part I: pharmacology, pharmacokinetics, and efficacy. Ann Pharmacother. 1999;33(1):73–85. https://doi.org/10.1345/aph.17215.
15. Farah A. Atypicality of atypical antipsychotics. Prim Care Companion J Clin Psychiatry. 2005;7(6):268–74.
16. Seeberger LC, Hauser RA. Valbenazine for the treatment of tardive dyskinesia. Expert Opin Pharmacother. 2017;18(12):1279–87. https://doi.org/10.1080/14656566.2017.1353078.
17. Remington G. Tardive dyskinesia: eliminated, forgotten, or overshadowed? Curr Opin Psychiatry. 2007;20(2):131–7. https://doi.org/10.1097/YCO.0b013e328017f6b1.
18. Doepp S, Buddeberg C. Extrapyramidal symptoms following clozapine therapy. Case report. Der Nervenarzt. 1975;46(10):589–90.
19. Das S, Purushothaman ST, Rajan V, Chatterjee SS, Kartha A. Clozapine-induced tardive dyskinesia. Indian J Psychol Med. 2017;39(4):551–2. https://doi.org/10.4103/IJPSYM.IJPSYM_194_17.
20. Li CR, Chung YC, Park TW, Yang JC, Kim KW, Lee KH, et al. Clozapine-induced tardive dyskinesia in schizophrenic patients taking clozapine as a first-line antipsychotic drug. World J Biol Psychiatry. 2009;10(4 Pt 3):919–24. https://doi.org/10.1080/15622970802481895.
21. Mendhekar DN, Andrade C. Prochlorperazine-induced tardive dystonia and its worsening with clozapine in a non-mentally ill patient with migraine. Ann Pharmacother. 2011;45(4):545–6. https://doi.org/10.1345/aph.1P194.
22. Uzun O, Doruk A. Tardive oculogyric crisis during treatment with clozapine: report of three cases. Clin Drug Invest. 2007;27(12):861–4.
23. Raguraman J, Vijaysagar J. Worsening of tardive dyskinesia due to clozapine therapy. J Postgrad Med. 2007;53(3):218. https://doi.org/10.4103/0022-3859.33874.
24. Hung TH, Lee Y, Chang YY, Chong MY, Lin PY. Reversible pisa syndrome induced by clozapine: a case report. Clin Neuropharmacol. 2007;30(6):370–2. https://doi.org/10.1097/WNF.0b013e31805930e3.
25. Lin CC, Bai YM, Chen JY, Wang YC, Liou YJ. Treatment of clozapine-associated tardive dyskinesia. Prog Neuro-Psychopharmacol Biol Psychiatry. 2008;32(2):599–600. https://doi.org/10.1016/j.pnpbp.2007.09.009.
26. Bruscas MJ, Gonzalez F, Santos JL, Sanchez E. Tardive dyskinesia associated with clozapine treatment. Prog Neuro-Psychopharmacol Biol Psychiatry. 2007;31(4):963–4. https://doi.org/10.1016/j.pnpbp.2007.01.016.
27. Mendhekar DN, Duggal HS. Clozapine-induced tardive dyskinesia and hypothyroidism. J Neuropsychiatry Clin Neurosci. 2006;18(2):245–6. https://doi.org/10.1176/jnp.2006.18.2.245.
28. Ertugrul A, Demir B. Clozapine-induced tardive dyskinesia: a case report. Prog Neuro-Psychopharmacol Biol Psychiatry. 2005;29(4):633–5. https://doi.org/10.1016/j.pnpbp.2005.01.014.
29. Miller DD. Clozapine and tardive dyskinesia. Am J Psychiatry. 2003;160(3):588. https://doi.org/10.1176/appi.ajp.160.3.588.
30. Molho ES, Factor SA. Possible tardive dystonia resulting from clozapine therapy. Mov Disord. 1999;14(5):873–4.
31. Bruneau MA, Stip E. Metronome or alternating pisa syndrome: a form of tardive dystonia under clozapine treatment. Int Clin Psychopharmacol. 1998;13(5):229–32.
32. Peacock L, Solgaard T, Lublin H, Gerlach J. Clozapine versus typical antipsychotics. A retro- and prospective study of extrapyramidal side effects. Psychopharmacology. 1996;124(1–2):188–96.
33. de Leon J, Moral L, Camunas C. Clozapine and jaw dyskinesia: a case report. J Clin Psychiatry. 1991;52(12):494–5.
34. Wirshing WC, Phelan CK, van Putten T, Marder SR, Engel J. Effects of clozapine on treatment-resistant akathisia and concomitant tardive dyskinesia. J Clin Psychopharmacol. 1990;10(5):371–3.
35. Casey DE. Clozapine: neuroleptic-induced EPS and tardive dyskinesia. Psychopharmacology. 1989;99(Suppl):S47–53.
36. Kane JM, Woerner MG, Pollack S, Safferman AZ, Lieberman JA. Does clozapine cause tardive-dyskinesia. J Clin Psychiatry. 1993;54(9):327–30.
37. Dave M. Clozapine-related tardive-dyskinesia. Biol Psychiatry. 1994;35(11):886–7. https://doi.org/10.1016/0006-3223(94)90025-6.
38. Hazari N, Kate N, Grover S. Clozapine and tardive movement disorders: a review. Asian J Psychiatry. 2013;6(6):439–51. https://doi.org/10.1016/j.ajp.2013.08.067.
39. Meyer JM. Forgotten but not gone: new developments in the understanding and treatment of tardive dyskinesia. CNS Spectr. 2016;21(S1):13–24. https://doi.org/10.1017/S1092852916000730.
40. Tenback DE, van Harten PN. Epidemiology and risk factors for (tardive) dyskinesia. Int Rev Neurobiol. 2011;98:211–30. https://doi.org/10.1016/B978-0-12-381328-2.00009-2.
41. Rakesh G, Muzyk A, Szabo ST, Gupta S, Pae CU, Masand P. Tardive dyskinesia: 21st century may bring new treatments to a forgotten disorder. Ann Clin Psychiatry. 2017;29(2):108–19.
42. Fujimaki K, Morinobu S, Yamashita H, Takahashi T, Yamawaki S. Predictors of quality of life in inpatients with schizophrenia. Psychiatry Res. 2012;197(3):199–205. https://doi.org/10.1016/j.psychres.2011.10.023.
43. Cuesta MJ, Garcia de Jalon E, Campos MS, Moreno-Izco L, Lorente-Omenaca R, Sanchez-Torres AM, et al. Motor abnormalities in first-episode psychosis patients and long-term psychosocial functioning. Schizophr Res. 2017. https://doi.org/10.1016/j.schres.2017.08.050.
44. Carbon M, Hsieh CH, Kane JM, Correll CU. Tardive dyskinesia prevalence in the period of second-generation antipsychotic use: a meta-analysis. J Clin Psychiat. 2017;78(3):E264–78. https://doi.org/10.4088/Jcp.16r10832.
45. Correll CU, Schenk EM. Tardive dyskinesia and new antipsychotics. Curr Opin Psychiatry. 2008;21(2):151–6. https://doi.org/10.1097/YCO.0b013e3282f53132.
46. Correll CU, Leucht S, Kane JM. Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies. Am J Psychiatry. 2004;161(3):414–25. https://doi.org/10.1176/appi.ajp.161.3.414.
47. Miller DD, Caroff SN, Davis SM, Rosenheck RA, McEvoy JP, Saltz BL, et al. Extrapyramidal side-effects of antipsychotics in a randomised trial. Brit J Psychiatry. 2008;193(4):279–88. https://doi.org/10.1192/bjp.bp.108.050088.
48. de Leon J. The effect of atypical versus typical antipsychotics on tardive dyskinesia—a naturalistic study. Eur Arch Psy Clin N. 2007;257(3):169–72. https://doi.org/10.1007/s00406-006-0705-z.
49. Mentzel TQ, Lieverse R, Bloemen O, Viechtbauer W, van Harten PN, Genetic R, et al. High incidence and prevalence of drug-related movement disorders in young patients with psychotic disorders. J Clin Psychopharmacol. 2017;37(2):231–8. https://doi.org/10.1097/JCP.0000000000000666.
50. Parksepp M, Ljubajev U, Taht K, Janno S. Prevalence of neuroleptic-induced movement disorders: an 8-year follow-up study in chronic schizophrenia inpatients. Nordic J Psychiatry. 2016;70(7):498–502. https://doi.org/10.3109/08039488.2016.1164245.
51. Nakata Y, Kanahara N, Kimura H, Watanabe H, Iyo M. Efficacy of clozapine on dopamine supersensitivity psychosis in schizophrenia. Int Clin Psychopharmacol. 2017;32(3):169–73. https://doi.org/10.1097/YIC.0000000000000160.
52. O’Brien A. Comparing the risk of tardive dyskinesia in older adults with first-generation and second-generation antipsychotics: a systematic review and meta-analysis. Int J Geriatr Psychiatry. 2016;31(7):683–93. https://doi.org/10.1002/gps.4399.
53. Dean CE, Kuskowski MA, Caligiuri MP. Predictors of neuroleptic-induced dyskinesia and parkinsonism: the influence of measurement methods and definitions. J Clin Psychopharmacol. 2006;26(6):560–5. https://doi.org/10.1097/01.jcp.0000245559.14284.e3.
54. Tenback DE, van Harten PN, Slooff CJ, van Os J. Evidence that early extrapyramidal symptoms predict later tardive dyskinesia: a prospective analysis of 10,000 patients in the European schizophrenia outpatient health outcomes (SOHO) study. Am J Psychiat. 2006;163(8):1438–40. https://doi.org/10.1176/appi.ajp.163.8.1438.
55. Klawans HL Jr, Rubovits R. An experimental model of tardive dyskinesia. J Neural Transm. 1972;33(3):235–46.
56. Tarsy D, Baldessarini RJ. Pharmacologically induced behavioural supersensitivity to apomorphine. Nature. 1973;245(148):262–3.
57. Cloud LJ, Zutshi D, Factor SA. Tardive dyskinesia: therapeutic options for an increasingly common disorder. Neurotherapeutics. 2014;11(1):166–76. https://doi.org/10.1007/s13311-013-0222-5.
58. Casey DE. Pathophysiology of antipsychotic drug-induced movement disorders. J Clin Psychiatry. 2004;65(Suppl 9):25–8.
59. Waddington JL, Cross AJ, Gamble SJ, Bourne RC. Spontaneous orofacial dyskinesia and dopaminergic function in rats after 6 months of neuroleptic treatment. Science. 1983;220(4596):530–2.
60. Crow TJ, Cross AJ, Johnstone EC, Owen F, Owens DGC, Waddington JL. Abnormal involuntary movements in schizophrenia—are they related to the disease process or its treatment—are they associated with changes in dopamine-receptors. J Clin Psychopharmacol. 1982;2(5):336–40.
61. Casey DE. Tardive dyskinesia: pathophysiology and animal models. J Clin Psychiatry. 2000;61(Suppl 4):5–9.
62. Casey DE, Gerlach J, Magelund G, Christensen TR. gamma-Acetylenic GABA in tardive dyskinesia. Arch Gen Psychiatry. 1980;37(12):1376–9.
63. Gunne LM, Haggstrom JE, Sjoquist B. Association with persistent neuroleptic-induced dyskinesia of regional changes in brain GABA synthesis. Nature. 1984;309(5966):347–9.
64. Thaker GK, Tamminga CA, Alphs LD, Lafferman J, Ferraro TN, Hare TA. Brain gamma-aminobutyric acid abnormality in tardive dyskinesia. Reduction in cerebrospinal fluid GABA levels and therapeutic response to GABA agonist treatment. Arch Gen Psychiatry. 1987;44(6):522–9.
65. Perry TL, Hansen S, Jones K. Schizophrenia, tardive dyskinesia, and brain GABA. Biol Psychiat. 1989;25(2):200–6.
66. Levesque C, Hernandez G, Mahmoudi S, Calon F, Gasparini F, Gomez-Mancilla B, et al. Deficient striatal adaptation in aminergic and glutamatergic neurotransmission is associated with tardive dyskinesia in non-human primates exposed to antipsychotic drugs. Neuroscience. 2017;361:43–57. https://doi.org/10.1016/j.neuroscience.2017.07.068.
67. Mahadik SP, Laev H, Korenovsky A, Karpiak SE. Haloperidol alters rat CNS cholinergic system: enzymatic and morphological analyses. Biol Psychiat. 1988;24(2):199–217.
68. Blanchet PJ, Parent MT, Rompre PH, Levesque D. Relevance of animal models to human tardive dyskinesia. Behavioral and brain functions: BBF. 2012;8:12. https://doi.org/10.1186/1744-9081-8-12.
69. Muller DJ, Schulze TG, Knapp M, Held T, Krauss H, Weber T, et al. Familial occurrence of tardive dyskinesia. Acta Psychiatr Scand. 2001;104(5):375–9.
70. Weinhold P, Wegner JT, Kane JM. Familial occurrence of tardive dyskinesia. J Clin Psychiatry. 1981;42(4):165–6.
71. Yassa R, Ananth J. Familial tardive dyskinesia. Am J Psychiatry. 1981;138(12):1618–9. https://doi.org/10.1176/ajp.138.12.1618.
72. Youssef H, Lyster G, Youssef F. Familial psychosis and vulnerability to tardive dyskinesia. Int Clin Psychopharmacol. 1989;4(4):323–8.
73. MacNeil RR, Muller DJ. Genetics of common antipsychotic-induced adverse effects. Mol Neuropsychiatry. 2016;2(2):61–78. https://doi.org/10.1159/000445802.
74. Tsai G, Goff DC, Chang RW, Flood J, Baer L, Coyle JT. Markers of glutamatergic neurotransmission and oxidative stress associated with tardive dyskinesia. Am J Psychiatry. 1998;155(9):1207–13. https://doi.org/10.1176/ajp.155.9.1207.
75. Walther S, Schappi L, Federspiel A, Bohlhalter S, Wiest R, Strik W, et al. Resting-state hyperperfusion of the supplementary motor area in catatonia. Schizophr Bull. 2016. https://doi.org/10.1093/schbul/sbw140.
76. Walther S. Psychomotor symptoms of schizophrenia map on the cerebral motor circuit. Psychiatry Res. 2015;233(3):293–8. https://doi.org/10.1016/j.pscychresns.2015.06.010.
77. Stegmayer K, Horn H, Federspiel A, Razavi N, Bracht T, Laimbock K, et al. Supplementary motor area (SMA) volume is associated with psychotic aberrant motor behaviour of patients with schizophrenia. Psychiatry Res. 2014;223(1):49–51. https://doi.org/10.1016/j.pscychresns.2014.05.002.
78. Walther S, Stegmayer K, Federspiel A, Bohlhalter S, Wiest R, Viher PV. Aberrant hyperconnectivity in the motor system at rest is linked to motor abnormalities in schizophrenia spectrum disorders. Schizophr Bull. 2017;43(5):982–92. https://doi.org/10.1093/schbul/sbx091.
79. Hirjak D, Wolf RC, Wilder-Smith EP, Kubera KM, Thomann PA. Motor abnormalities and basal ganglia in schizophrenia: evidence from structural magnetic resonance imaging. Brain Topogr. 2015;28(1):135–52. https://doi.org/10.1007/s10548-014-0377-3.
80. Schroder J, Wenz F, Schad LR, Baudendistel K, Knopp MV. Sensorimotor cortex and supplementary motor area changes in schizophrenia. A study with functional magnetic resonance imaging. Br J Psychiatry. 1995;167(2):197–201.
81. Martino M, Magioncalda P, Yu H, Li X, Wang Q, Meng Y, et al. Abnormal resting-state connectivity in a substantia nigra-related striato-thalamo-cortical network in a large sample of first-episode drug-naive patients with schizophrenia. Schizophr Bull. 2017. https://doi.org/10.1093/schbul/sbx067.
82. Bai YM, Chou KH, Lin CP, Chen IY, Li CT, Yang KC, et al. White matter abnormalities in schizophrenia patients with tardive dyskinesia: a diffusion tensor image study. Schizophr Res. 2009;109(1–3):167–81. https://doi.org/10.1016/j.schres.2009.02.003.
83. Macpherson R, Collis R. Tardive dyskinesia. Patients’ lack of awareness of movement disorder. Br J Psychiatry. 1992;160:110–2.
84. Caroff SN, Campbell EC, Carroll B. Pharmacological treatment of tardive dyskinesia: recent developments. Expert Rev Neurother. 2017;17(9):871–81. https://doi.org/10.1080/14737175.2017.1358616.
85. Koning JP, Tenback DE, Kahn RS, Van Schelven LJ, Van Harten PN. Instrument measurement of lingual force variability reflects tardive tongue dyskinesia. J Med Eng Technol. 2010;34(1):71–7. https://doi.org/10.3109/03091900903402105.
86. Koshino Y, Wada Y, Isaki K, Kurata K. A long-term outcome study of tardive dyskinesia in patients on antipsychotic medication. Clin Neuropharmacol. 1991;14(6):537–46.
87. Gardos G, Cole JO, Perenyi A, Casey DE, Samu I, Kallos M, et al. Five-year follow-up study of tardive dyskinesia. Adv Biochem Psychopharmacol. 1985;40:37–42.
88. Soares-Weiser K, Rathbone J. Neuroleptic reduction and/or cessation and neuroleptics as specific treatments for tardive dyskinesia. Cochrane Databse Syst Rev. 2006;1:CD000459 (Artn Cd00045910.1002/14651858.Cd000459.Pub2).
89. Glazer WM, Hafez HM, Benarroche CL. Molindone and haloperidol in tardive dyskinesia. J Clin Psychiatry. 1985;46(8 Pt 2):4–7.
90. Kazamatsuri H, Chien C, Cole JO. Treatment of tardive dyskinesia. II. Short-term efficacy of dopamine-blocking agents haloperidol and thiopropazate. Arch Gen Psychiatry. 1972;27(1):100–3.
91. Mentzel CL, Bakker PR, van Os J, Drukker M, Matroos GE, Hoek HW, et al. Effect of antipsychotic type and dose changes on tardive dyskinesia and parkinsonism severity in patients with a serious mental illness: the curacao extrapyramidal syndromes study XII. J Clin Psychiatry. 2017;78(3):e279–85. https://doi.org/10.4088/JCP.16m11049.
92. Bai YM, Yu SC, Chen JY, Lin CY, Chou P, Lin CC. Risperidone for pre-existing severe tardive dyskinesia: a 48-week prospective follow-up study. Int Clin Psychopharm. 2005;20(2):79–85. https://doi.org/10.1097/00004850-200503000-00003.
93. Chan HY, Chiang SC, Chang CJ, Gau SS, Chen JJ, Chen CH, et al. A randomized controlled trial of risperidone and olanzapine for schizophrenic patients with neuroleptic-induced tardive dyskinesia. J Clin Psychiatry. 2010;71(9):1226–33.
94. Ono S, Suzuki Y, Shindo M, Endo T, Fukui N, Sugai T, et al. Improvement of tardive dyskinesia and dystonia associated with aripiprazole following a switch to quetiapine: case report and review of the literature. J Clin Pharm Ther. 2012;37(3):370–2. https://doi.org/10.1111/j.1365-2710.2011.01290.x.
95. Louza MR, Bassitt DP. Maintenance treatment of severe tardive dyskinesia with clozapine: 5 years’ follow-up. J Clin Psychopharmacol. 2005;25(2):180–2 (00004714-200504000-00012 [pii]).
96. Spivak B, Mester R, Abesgaus J, Wittenberg N, Adlersberg S, Gonen N, et al. Clozapine treatment for neuroleptic-induced tardive dyskinesia, parkinsonism, and chronic akathisia in schizophrenic patients. J Clin Psychiatry. 1997;58(7):318–22.
97. Moore NC, Lewitt PA, Gershon S. Reduction of dyskinesias and psychiatric disability with clozapine over different time courses. J Psychopharmacol. 1992;6(4):514–8. https://doi.org/10.1177/026988119200600407.
98. Bergman H, Walker DM, Nikolakopoulou A, Soares-Weiser K, Adams CE. Systematic review of interventions for treating or preventing antipsychotic-induced tardive dyskinesia. Health Technol Assess. 2017;21(43):1–218. https://doi.org/10.3310/hta21430.
99. Kane JM, Rifkin A, Woerner M, Reardon G, Sarantakos S, Schiebel D, et al. Low-dose neuroleptic treatment of outpatient schizophrenics. 1. preliminary-results for relapse rates. Arch Gen Psychiatry. 1983;40(8):893–6.
100. Cookson IB. The effects of a 50-percent reduction of cis(z)-flupentixol decanoate in chronic-schizophrenic patients maintained on a high-dose regime. Int Clin Psychopharm. 1987;2(2):141–9. https://doi.org/10.1097/00004850-198704000-00008.
101. Casey DE, Toenniessen LM. Neuroleptic treatment in tardive dyskinesia: can it be developed into a clinical strategy for long-term treatment? Mod Probl Pharmacopsychiatry. 1983;21:65–79.
102. Yassa R, Nair NP. A 10-year follow-up study of tardive dyskinesia. Acta Psychiatr Scand. 1992;86(4):262–6.
103. Yassa R, Nair V, Schwartz G. Tardive dyskinesia: a two-year follow-up study. Psychosomatics. 1984;25(11):852–5. https://doi.org/10.1016/S0033-3182(84)72946-X.
104. Yagi G, Itoh H. A 10-year follow-up study of tardive dyskinesia–with special reference to the influence of neuroleptic administration on the long-term prognosis. Keio J Med. 1985;34(4):211–9.
105. Bai YM, Yu SC, Lin CC. Risperidone for severe tardive dyskinesia: a 12-week randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2003;64(11):1342–8.
106. Chouinard G. Effects of risperidone in tardive dyskinesia: an analysis of the Canadian multicenter risperidone study. J Clin Psychopharmacol. 1995;15(1 Suppl 1):36S–44S.
107. Tamminga CA, Thaker GK, Moran M, Kakigi T, Gao XM. Clozapine in tardive dyskinesia: observations from human and animal model studies. J Clin Psychiatry. 1994;55(Suppl B):102–6.
108. Emsley R, Turner HJ, Schronen J, Botha K, Smit R, Oosthuizen PP. A single-blind, randomized trial comparing quetiapine and haloperidol in the treatment of tardive dyskinesia. J Clin Psychiatry. 2004;65(5):696–701.
109. Caroff SN, Davis VG, Miller DD, Davis SM, Rosenheck RA, McEvoy JP, et al. Treatment outcomes of patients with tardive dyskinesia and chronic schizophrenia. J Clin Psychiatry. 2011;72(3):295–303. https://doi.org/10.4088/JCP.09m05793yel.
110. Emsley R, Turner J, Schronen J, Botha K, Smit R, Oosthuizen P. Quetiapine shows greater improvements in tardive dyskinesia compared with haloperidol. European Psychiatry. 2004;19:178s–9s.
111. Miller DD, McEvoy JP, Davis SM, Caroff SN, Saltz BL, Chakos MH, et al. Clinical correlates of tardive dyskinesia in schizophrenia: baseline data from the CATIE schizophrenia trial. Schizophr Res. 2005;80(1):33–43. https://doi.org/10.1016/j.schres.2005.07.034.
112. Tarsy D, Lungu C, Baldessarini RJ. Epidemiology of tardive dyskinesia before and during the era of modern antipsychotic drugs. Handbook Clin Neurol. 2011;100:601–16. https://doi.org/10.1016/B978-0-444-52014-2.00043-4.
113. Caykoylu A, Ekinci O, Yilmaz E. Resolution of risperidone-induced tardive dyskinesia with a switch to aripiprazole monotherapy. Prog Neuropsychopharmacol Biol Psychiatry. 2009;33(3):571–2. https://doi.org/10.1016/j.pnpbp.2009.01.009.
114. Schwartz T, Raza S. Aripiprazole (abilify) and tardive dyskinesia. P T. 2008;33(1):32–4.
115. Wunderink L, Nieboer RM, Wiersma D, Sytema S, Nienhuis FJ. Recovery in remitted first-episode psychosis at 7 years of follow-up of an early dose reduction/discontinuation or maintenance treatment strategy long-term follow-up of a 2-year randomized clinical trial. Jama Psychiat. 2013;70(9):913–20. https://doi.org/10.1001/jamapsychiatry.2013.19.
116. Alabed S, Latifeh Y, Mohammad HA, Rifai A. Gamma-aminobutyric acid agonists for neuroleptic-induced tardive dyskinesia. Cochrane Database Syst Rev. 2011;4:000203. https://doi.org/10.1002/14651858.cd000203.pub3.
117. Bhoopathi PS, Soares-Weiser K. Benzodiazepines for neuroleptic-induced tardive dyskinesia. Cochrane Database Syst Rev. 2006;3:CD000205. https://doi.org/10.1002/14651858.cd000205.pub2.
118. Essali A, Deirawan H, Soares-Weiser K, Adams CE. Calcium channel blockers for neuroleptic-induced tardive dyskinesia. Cochrane Database Syst Rev. 2011;11:CD000206. https://doi.org/10.1002/14651858.cd000206.pub3.
119. El-Sayeh HG, Lyra da Silva JP, Rathbone J, Soares-Weiser K. Non-neuroleptic catecholaminergic drugs for neuroleptic-induced tardive dyskinesia. Cochrane Database Syst Rev. 2006;1:CD000458. https://doi.org/10.1002/14651858.cd000458.pub2.
120. Adelufosi AO, Abayomi O, Ojo TM. Pyridoxal 5 phosphate for neuroleptic-induced tardive dyskinesia. Cochrane Database Syst Rev. 2015;4:CD010501. https://doi.org/10.1002/14651858.cd010501.pub2.
121. Soares-Weiser K, Maayan N, McGrath J. Vitamin E for neuroleptic-induced tardive dyskinesia. Cochrane Database Syst Rev. 2011;2:CD000209. https://doi.org/10.1002/14651858.cd000209.pub2.
122. Weber SS, Dufresne RL, Becker RE, Mastrati P. Diazepam in tardive dyskinesia. Drug Intell Clin Pharm. 1983;17(7–8):523–7.
123. Csernansky JG, Tacke U, Rusen D, Hollister LE. The effect of benzodiazepines on tardive dyskinesia symptoms. J Clin Psychopharmacol. 1988;8(2):154–5.
124. Csernansky JG, Riney SJ, Lombrozo L, Overall JE, Hollister LE. Double-blind comparison of alprazolam, diazepam, and placebo for the treatment of negative schizophrenic symptoms. Arch Gen Psychiatry. 1988;45(7):655–9.
125. Bobruff A, Gardos G, Tarsy D, Rapkin RM, Cole JO, Moore P. Clonazepam and phenobarbital in tardive dyskinesia. Am J Psychiatry. 1981;138(2):189–93. https://doi.org/10.1176/ajp.138.2.189.
126. Greil W, Haag H, Rossnagl G, Ruther E. Effect of anticholinergics on tardive dyskinesia. A controlled discontinuation study. Br J Psychiatry. 1984;145:304–10.
127. Woods SW, Saksa JR, Baker CB, Cohen SJ, Tek C. Effects of levetiracetam on tardive dyskinesia: a randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2008;69(4):546–54.
128. Dalby MA. Effect of tetrabenazine on extrapyramidal movement disorders. BMJ. 1969;2(5654):422–3.
129. MacCallum WA. Tetrabenazine for extra-pyramidal movement disorders. BMJ. 1970;1(5698):760.
130. Brandrup E. Tetrabenacine treatment in persisting dyskinesia caused by psychopharmaca. Am J Psychiatry. 1961;118:551–2. https://doi.org/10.1176/ajp.118.6.551.
131. Kazamatsuri H, Chien CP, Cole JO. Long-term treatment of tardive dyskinesia with haloperidol and tetrabenazine. Am J Psychiatry. 1973;130(4):479–83.
132. O’Brien CF, Jimenez R, Hauser RA, Factor SA, Burke J, Mandri D, et al. NBI-98854, a selective monoamine transport inhibitor for the treatment of tardive dyskinesia: A randomized, double-blind, placebo-controlled study. Mov Disord. 2015;30(12):1681–7. https://doi.org/10.1002/mds.26330.
133. Hauser RA, Factor SA, Marder SR, Knesevich MA, Ramirez PM, Jimenez R, et al. KINECT 3: A phase 3 randomized, double-blind, placebo-controlled trial of valbenazine for tardive dyskinesia. Am J Psychiatry. 2017;174(5):476–84. https://doi.org/10.1176/appi.ajp.2017.16091037.
134. Josiassen RC, Kane JM, Liang GS, Burke J, O’Brien CF. Long-term safety and tolerability of valbenazine (NBI-98854) in subjects with tardive dyskinesia and a diagnosis of schizophrenia or mood disorder. Psychopharmacol Bull. 2017;47(3):61–8.
135. Fernandez HH, Factor SA, Hauser RA, Jimenez-Shahed J, Ondo WG, Jarskog LF, et al. Randomized controlled trial of deutetrabenazine for tardive dyskinesia: The ARM-TD study. Neurology. 2017;88(21):2003–10. https://doi.org/10.1212/WNL.0000000000003960.
136. Anderson KE, Stamler D, Davis MD, Factor SA, Hauser RA, Isojarvi J, et al. Deutetrabenazine for treatment of involuntary movements in patients with tardive dyskinesia (AIM-TD): a double-blind, randomised, placebo-controlled, phase 3 trial. The lancet Psychiatry. 2017;4(8):595–604. https://doi.org/10.1016/S2215-0366(17)30236-5.
137. van Harten PN, Hovestadt A. Botulinum toxin as a treatment for tardive dyskinesia. Mov Disord. 2006;21(8):1276–7.
138. Tschopp L, Salazar Z, Micheli F. Botulinum toxin in painful tardive dyskinesia. Clin Neuropharmacol. 2009;32(3):165–6. https://doi.org/10.1097/WNF.0b013e31818ddbc4.
139. Esper CD, Freeman A, Factor SA. Lingual protrusion dystonia: frequency, etiology and botulinum toxin therapy. Parkinsonism Relat Disord. 2010;16(7):438–41. https://doi.org/10.1016/j.parkreldis.2010.04.007.
140. Hennings JM, Krause E, Botzel K, Wetter TC. Successful treatment of tardive lingual dystonia with botulinum toxin: case report and review of the literature. Prog Neuropsychopharmacol Biol Psychiatry. 2008;32(5):1167–71. https://doi.org/10.1016/j.pnpbp.2007.09.010.
141. Slotema CW, van Harten PN, Bruggeman R, Hoek HW. Botulinum toxin in the treatment of orofacial tardive dyskinesia: a single blind study. Prog Neuropsychopharmacol Biol Psychiatry. 2008;32(2):507–9. https://doi.org/10.1016/j.pnpbp.2007.10.004.
142. Damier P, Thobois S, Witjas T, Cuny E, Derost P, Raoul S, et al. Bilateral deep brain stimulation of the globus pallidus to treat tardive dyskinesia. Arch Gen Psychiatry. 2007;64(2):170–6. https://doi.org/10.1001/archpsyc.64.2.170.
143. Schrader C, Peschel T, Petermeyer M, Dengler R, Hellwig D. Unilateral deep brain stimulation of the internal globus pallidus alleviates tardive dyskinesia. Mov Disord. 2004;19(5):583–5. https://doi.org/10.1002/mds.10705.
144. Zhang JG, Zhang K, Wang ZC. Deep brain stimulation in the treatment of tardive dystonia. Chin Med J. 2006;119(9):789–92.
145. Mentzel CL, Tenback DE, Tijssen MA, Visser-Vandewalle VE, van Harten PN. Efficacy and safety of deep brain stimulation in patients with medication-induced tardive dyskinesia and/or dystonia: a systematic review. J Clin Psychiatry. 2012;73(11):1434–8. https://doi.org/10.4088/JCP.12r07643.
146. Johnsen M, Wester K. Full remission of tardive dyskinesia following general anaesthesia. J Neurol. 2002;249(5):622–5. https://doi.org/10.1007/s004150200073.
147. Spindler MA, Galifianakis NB, Wilkinson JR, Duda JE. Globus pallidus interna deep brain stimulation for tardive dyskinesia: case report and review of the literature. Parkinsonism Relat Disord. 2013;19(2):141–7. https://doi.org/10.1016/j.parkreldis.2012.09.016.
148. Pouclet-Courtemanche H, Rouaud T, Thobois S, Nguyen JM, Brefel-Courbon C, Chereau I, et al. Long-term efficacy and tolerability of bilateral pallidal stimulation to treat tardive dyskinesia. Neurology. 2016;86(7):651–9. https://doi.org/10.1212/WNL.0000000000002370.
149. Kefalopoulou Z, Paschali A, Markaki E, Vassilakos P, Ellul J, Constantoyannis C. A double-blind study on a patient with tardive dyskinesia treated with pallidal deep brain stimulation. Acta Neurol Scand. 2009;119(4):269–73. https://doi.org/10.1111/j.1600-0404.2008.01115.x.